Chronic exposure to cocaine is associated with persistent behavioral disturbances. A cross-sectional dimensional study in outpatients with multiple substance use disorders.
Identifieur interne : 000272 ( Main/Exploration ); précédent : 000271; suivant : 000273Chronic exposure to cocaine is associated with persistent behavioral disturbances. A cross-sectional dimensional study in outpatients with multiple substance use disorders.
Auteurs : Florence Vorspan [France] ; Pauline De Witt [France] ; El-Hadi Zerdazi [France] ; Emily Karsinti [France] ; Kamilia Ksouda [Tunisie] ; Romain Icick [France] ; Frank Bellivier [France] ; Nicolas Marie [France] ; Georges Brousse [France] ; Vanessa Bloch [France]Source :
- Psychopharmacology [ 1432-2072 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Cocaïne (administration et posologie), Cocaïne (effets indésirables), Diagnostic and stastistical manual of mental disorders (USA) (MeSH), Facteurs de risque (MeSH), Femelle (MeSH), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Patients en consultation externe (psychologie), Soins ambulatoires (tendances), Troubles liés à la cocaïne (diagnostic), Troubles liés à une substance (diagnostic), Troubles liés à une substance (épidémiologie), Troubles mentaux (diagnostic), Troubles mentaux (induit chimiquement), Troubles mentaux (épidémiologie), Études transversales (MeSH).
- MESH :
- administration et posologie : Cocaïne.
- diagnostic : Troubles liés à la cocaïne, Troubles liés à une substance, Troubles mentaux.
- effets indésirables : Cocaïne.
- induit chimiquement : Troubles mentaux.
- psychologie : Patients en consultation externe.
- tendances : Soins ambulatoires.
- épidémiologie : Troubles liés à une substance, Troubles mentaux.
- Adulte, Adulte d'âge moyen, Diagnostic and stastistical manual of mental disorders (USA), Facteurs de risque, Femelle, Humains, Jeune adulte, Mâle, Études transversales.
English descriptors
- KwdEn :
- Adult (MeSH), Ambulatory Care (trends), Cocaine (administration & dosage), Cocaine (adverse effects), Cocaine-Related Disorders (diagnosis), Cross-Sectional Studies (MeSH), Diagnostic and Statistical Manual of Mental Disorders (MeSH), Female (MeSH), Humans (MeSH), Male (MeSH), Mental Disorders (chemically induced), Mental Disorders (diagnosis), Mental Disorders (epidemiology), Middle Aged (MeSH), Outpatients (psychology), Risk Factors (MeSH), Substance-Related Disorders (diagnosis), Substance-Related Disorders (epidemiology), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Cocaine.
- chemical , adverse effects : Cocaine.
- chemically induced : Mental Disorders.
- diagnosis : Cocaine-Related Disorders, Mental Disorders, Substance-Related Disorders.
- epidemiology : Mental Disorders, Substance-Related Disorders.
- psychology : Outpatients.
- trends : Ambulatory Care.
- Adult, Cross-Sectional Studies, Diagnostic and Statistical Manual of Mental Disorders, Female, Humans, Male, Middle Aged, Risk Factors, Young Adult.
Abstract
RATIONALE
Behavioral disturbances (BD) are prevalent in patients with substance use disorders (SUD).
OBJECTIVES
To test the hypothesis that chronic exposure to cocaine could favor the acquisition of BD that were not present in childhood.
METHODS
We used child and adult ADHD self-report screening scales (WURS-25 and ASRS-6, respectively, with their usual threshold) as assessment tools for significant BD. In a cross-sectional assessment of 382 patients with multiple SUD, we investigated BD and then "de novo" BD (i.e., by restricting the sample to patients below the threshold for childhood BD) (N = 214). We also tested for a gradient effect between patients' lifetime DSM IV cocaine and opioid dependence status and the prevalence of BD.
RESULTS
BD were found in 188/382 (42.9%) subjects and in 74/214 (34.6%) subjects. Three clinical factors were associated with BD in the whole sample: the number of cocaine dependence criteria (OR = 1.36 [1.14-1.64], p = 0.001), the number of opioid dependence criteria (OR = 0.69 [0.52-0.91], p = 0.010), and a personal history of using cocaine through rapid routes of administration (OR = 0.41 [0.19-0.88], p = 0.022). The same three factors were associated with "de novo" BD in the restricted sample: OR = 1.35 ([1.11-1.63], p = 0.002), OR = 0.83 ([0.70-0.99], p = 0.046), and OR 0.37 ([0.16-0.86], p = 0.022), respectively. There were significant gradients for BD according to the cocaine exposure categories in the whole (Mantel-Haenszel, p < 0.001) and in the restricted sample (Mantel-Haenszel, p = 0.002).
CONCLUSIONS
Cocaine exposure was positively associated with behavioral disturbances in a dose-dependent manner in this clinical sample, whilst opioid exposure showed a negative association.
DOI: 10.1007/s00213-020-05620-x
PubMed: 32748030
Affiliations:
- France, Tunisie
- Auvergne (région administrative), Auvergne-Rhône-Alpes, Île-de-France
- Clermont-Ferrand, Créteil, Nanterre, Paris
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chronic exposure to cocaine is associated with persistent behavioral disturbances. A cross-sectional dimensional study in outpatients with multiple substance use disorders.</title><author><name sortKey="Vorspan, Florence" sort="Vorspan, Florence" uniqKey="Vorspan F" first="Florence" last="Vorspan">Florence Vorspan</name><affiliation wicri:level="3"><nlm:affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France. florence.vorspan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Faculté de Médecine, Université de Paris, Paris, France. florence.vorspan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté de Médecine, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France. florence.vorspan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="De Witt, Pauline" sort="De Witt, Pauline" uniqKey="De Witt P" first="Pauline" last="De Witt">Pauline De Witt</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Service de Psychiatrie et d'Addictologie, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Psychiatrie et d'Addictologie, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Zerdazi, El Hadi" sort="Zerdazi, El Hadi" uniqKey="Zerdazi E" first="El-Hadi" last="Zerdazi">El-Hadi Zerdazi</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Service d'Addictologie, DHU Pe-Psy, Pôle de psychiatrie et d'addictologie, Hôpitaux universitaires Henri MONDOR, APHP, F94000, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Addictologie, DHU Pe-Psy, Pôle de psychiatrie et d'addictologie, Hôpitaux universitaires Henri MONDOR, APHP, F94000, Créteil</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Karsinti, Emily" sort="Karsinti, Emily" uniqKey="Karsinti E" first="Emily" last="Karsinti">Emily Karsinti</name><affiliation wicri:level="3"><nlm:affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 4430 CLIPSYD (Psychologie Clinique, Psychanalyse et Psychologie du Développement), UFR SPSE, Université Paris Nanterre, Nanterre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 4430 CLIPSYD (Psychologie Clinique, Psychanalyse et Psychologie du Développement), UFR SPSE, Université Paris Nanterre, Nanterre</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Nanterre</settlement></placeName></affiliation></author><author><name sortKey="Ksouda, Kamilia" sort="Ksouda, Kamilia" uniqKey="Ksouda K" first="Kamilia" last="Ksouda">Kamilia Ksouda</name><affiliation wicri:level="1"><nlm:affiliation>Faculté de Médecine de Sfax, Sfax, Tunisia.</nlm:affiliation><country xml:lang="fr">Tunisie</country><wicri:regionArea>Faculté de Médecine de Sfax, Sfax</wicri:regionArea><wicri:noRegion>Sfax</wicri:noRegion></affiliation></author><author><name sortKey="Icick, Romain" sort="Icick, Romain" uniqKey="Icick R" first="Romain" last="Icick">Romain Icick</name><affiliation wicri:level="3"><nlm:affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bellivier, Frank" sort="Bellivier, Frank" uniqKey="Bellivier F" first="Frank" last="Bellivier">Frank Bellivier</name><affiliation wicri:level="3"><nlm:affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Faculté de Médecine, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté de Médecine, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Marie, Nicolas" sort="Marie, Nicolas" uniqKey="Marie N" first="Nicolas" last="Marie">Nicolas Marie</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1124, "Environmental Toxicity, Therapeutic Targets, Cellular Signaling and Biomarkers", Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1124, "Environmental Toxicity, Therapeutic Targets, Cellular Signaling and Biomarkers", Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>CNRS ERL 3649, "Addiction Pharmacology and Therapy", Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS ERL 3649, "Addiction Pharmacology and Therapy", Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Brousse, Georges" sort="Brousse, Georges" uniqKey="Brousse G" first="Georges" last="Brousse">Georges Brousse</name><affiliation wicri:level="3"><nlm:affiliation>Inserm Umr 1107, Neuro-Dol, Université Clermont-Auvergne, Clermont-Ferrand, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm Umr 1107, Neuro-Dol, Université Clermont-Auvergne, Clermont-Ferrand</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Auvergne (région administrative)</region><settlement type="city">Clermont-Ferrand</settlement></placeName></affiliation></author><author><name sortKey="Bloch, Vanessa" sort="Bloch, Vanessa" uniqKey="Bloch V" first="Vanessa" last="Bloch">Vanessa Bloch</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Service de Pharmacie, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacie, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Faculté de Pharmacie de Paris, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté de Pharmacie de Paris, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32748030</idno><idno type="pmid">32748030</idno><idno type="doi">10.1007/s00213-020-05620-x</idno><idno type="wicri:Area/Main/Corpus">000112</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000112</idno><idno type="wicri:Area/Main/Curation">000112</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000112</idno><idno type="wicri:Area/Main/Exploration">000112</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Chronic exposure to cocaine is associated with persistent behavioral disturbances. A cross-sectional dimensional study in outpatients with multiple substance use disorders.</title><author><name sortKey="Vorspan, Florence" sort="Vorspan, Florence" uniqKey="Vorspan F" first="Florence" last="Vorspan">Florence Vorspan</name><affiliation wicri:level="3"><nlm:affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France. florence.vorspan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Faculté de Médecine, Université de Paris, Paris, France. florence.vorspan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté de Médecine, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France. florence.vorspan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="De Witt, Pauline" sort="De Witt, Pauline" uniqKey="De Witt P" first="Pauline" last="De Witt">Pauline De Witt</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Service de Psychiatrie et d'Addictologie, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Psychiatrie et d'Addictologie, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Zerdazi, El Hadi" sort="Zerdazi, El Hadi" uniqKey="Zerdazi E" first="El-Hadi" last="Zerdazi">El-Hadi Zerdazi</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Service d'Addictologie, DHU Pe-Psy, Pôle de psychiatrie et d'addictologie, Hôpitaux universitaires Henri MONDOR, APHP, F94000, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Addictologie, DHU Pe-Psy, Pôle de psychiatrie et d'addictologie, Hôpitaux universitaires Henri MONDOR, APHP, F94000, Créteil</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Karsinti, Emily" sort="Karsinti, Emily" uniqKey="Karsinti E" first="Emily" last="Karsinti">Emily Karsinti</name><affiliation wicri:level="3"><nlm:affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 4430 CLIPSYD (Psychologie Clinique, Psychanalyse et Psychologie du Développement), UFR SPSE, Université Paris Nanterre, Nanterre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 4430 CLIPSYD (Psychologie Clinique, Psychanalyse et Psychologie du Développement), UFR SPSE, Université Paris Nanterre, Nanterre</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Nanterre</settlement></placeName></affiliation></author><author><name sortKey="Ksouda, Kamilia" sort="Ksouda, Kamilia" uniqKey="Ksouda K" first="Kamilia" last="Ksouda">Kamilia Ksouda</name><affiliation wicri:level="1"><nlm:affiliation>Faculté de Médecine de Sfax, Sfax, Tunisia.</nlm:affiliation><country xml:lang="fr">Tunisie</country><wicri:regionArea>Faculté de Médecine de Sfax, Sfax</wicri:regionArea><wicri:noRegion>Sfax</wicri:noRegion></affiliation></author><author><name sortKey="Icick, Romain" sort="Icick, Romain" uniqKey="Icick R" first="Romain" last="Icick">Romain Icick</name><affiliation wicri:level="3"><nlm:affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bellivier, Frank" sort="Bellivier, Frank" uniqKey="Bellivier F" first="Frank" last="Bellivier">Frank Bellivier</name><affiliation wicri:level="3"><nlm:affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Faculté de Médecine, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté de Médecine, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Marie, Nicolas" sort="Marie, Nicolas" uniqKey="Marie N" first="Nicolas" last="Marie">Nicolas Marie</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1124, "Environmental Toxicity, Therapeutic Targets, Cellular Signaling and Biomarkers", Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1124, "Environmental Toxicity, Therapeutic Targets, Cellular Signaling and Biomarkers", Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>CNRS ERL 3649, "Addiction Pharmacology and Therapy", Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS ERL 3649, "Addiction Pharmacology and Therapy", Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Brousse, Georges" sort="Brousse, Georges" uniqKey="Brousse G" first="Georges" last="Brousse">Georges Brousse</name><affiliation wicri:level="3"><nlm:affiliation>Inserm Umr 1107, Neuro-Dol, Université Clermont-Auvergne, Clermont-Ferrand, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm Umr 1107, Neuro-Dol, Université Clermont-Auvergne, Clermont-Ferrand</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Auvergne (région administrative)</region><settlement type="city">Clermont-Ferrand</settlement></placeName></affiliation></author><author><name sortKey="Bloch, Vanessa" sort="Bloch, Vanessa" uniqKey="Bloch V" first="Vanessa" last="Bloch">Vanessa Bloch</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Service de Pharmacie, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacie, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Faculté de Pharmacie de Paris, Université de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté de Pharmacie de Paris, Université de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Psychopharmacology</title><idno type="eISSN">1432-2072</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Ambulatory Care (trends)</term><term>Cocaine (administration & dosage)</term><term>Cocaine (adverse effects)</term><term>Cocaine-Related Disorders (diagnosis)</term><term>Cross-Sectional Studies (MeSH)</term><term>Diagnostic and Statistical Manual of Mental Disorders (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Mental Disorders (chemically induced)</term><term>Mental Disorders (diagnosis)</term><term>Mental Disorders (epidemiology)</term><term>Middle Aged (MeSH)</term><term>Outpatients (psychology)</term><term>Risk Factors (MeSH)</term><term>Substance-Related Disorders (diagnosis)</term><term>Substance-Related Disorders (epidemiology)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Cocaïne (administration et posologie)</term><term>Cocaïne (effets indésirables)</term><term>Diagnostic and stastistical manual of mental disorders (USA) (MeSH)</term><term>Facteurs de risque (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Patients en consultation externe (psychologie)</term><term>Soins ambulatoires (tendances)</term><term>Troubles liés à la cocaïne (diagnostic)</term><term>Troubles liés à une substance (diagnostic)</term><term>Troubles liés à une substance (épidémiologie)</term><term>Troubles mentaux (diagnostic)</term><term>Troubles mentaux (induit chimiquement)</term><term>Troubles mentaux (épidémiologie)</term><term>Études transversales (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cocaine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cocaine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cocaïne</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Mental Disorders</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cocaine-Related Disorders</term><term>Mental Disorders</term><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Troubles liés à la cocaïne</term><term>Troubles liés à une substance</term><term>Troubles mentaux</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Cocaïne</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Mental Disorders</term><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Troubles mentaux</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Patients en consultation externe</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Outpatients</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Soins ambulatoires</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Ambulatory Care</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Troubles liés à une substance</term><term>Troubles mentaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cross-Sectional Studies</term><term>Diagnostic and Statistical Manual of Mental Disorders</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Diagnostic and stastistical manual of mental disorders (USA)</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Études transversales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>RATIONALE</b></p><p>Behavioral disturbances (BD) are prevalent in patients with substance use disorders (SUD).</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To test the hypothesis that chronic exposure to cocaine could favor the acquisition of BD that were not present in childhood.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We used child and adult ADHD self-report screening scales (WURS-25 and ASRS-6, respectively, with their usual threshold) as assessment tools for significant BD. In a cross-sectional assessment of 382 patients with multiple SUD, we investigated BD and then "de novo" BD (i.e., by restricting the sample to patients below the threshold for childhood BD) (N = 214). We also tested for a gradient effect between patients' lifetime DSM IV cocaine and opioid dependence status and the prevalence of BD.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>BD were found in 188/382 (42.9%) subjects and in 74/214 (34.6%) subjects. Three clinical factors were associated with BD in the whole sample: the number of cocaine dependence criteria (OR = 1.36 [1.14-1.64], p = 0.001), the number of opioid dependence criteria (OR = 0.69 [0.52-0.91], p = 0.010), and a personal history of using cocaine through rapid routes of administration (OR = 0.41 [0.19-0.88], p = 0.022). The same three factors were associated with "de novo" BD in the restricted sample: OR = 1.35 ([1.11-1.63], p = 0.002), OR = 0.83 ([0.70-0.99], p = 0.046), and OR 0.37 ([0.16-0.86], p = 0.022), respectively. There were significant gradients for BD according to the cocaine exposure categories in the whole (Mantel-Haenszel, p < 0.001) and in the restricted sample (Mantel-Haenszel, p = 0.002).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Cocaine exposure was positively associated with behavioral disturbances in a dose-dependent manner in this clinical sample, whilst opioid exposure showed a negative association.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32748030</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-2072</ISSN><JournalIssue CitedMedium="Internet"><Volume>237</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Psychopharmacology</Title><ISOAbbreviation>Psychopharmacology (Berl)</ISOAbbreviation></Journal><ArticleTitle>Chronic exposure to cocaine is associated with persistent behavioral disturbances. A cross-sectional dimensional study in outpatients with multiple substance use disorders.</ArticleTitle><Pagination><MedlinePgn>3399-3407</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00213-020-05620-x</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Behavioral disturbances (BD) are prevalent in patients with substance use disorders (SUD).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To test the hypothesis that chronic exposure to cocaine could favor the acquisition of BD that were not present in childhood.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used child and adult ADHD self-report screening scales (WURS-25 and ASRS-6, respectively, with their usual threshold) as assessment tools for significant BD. In a cross-sectional assessment of 382 patients with multiple SUD, we investigated BD and then "de novo" BD (i.e., by restricting the sample to patients below the threshold for childhood BD) (N = 214). We also tested for a gradient effect between patients' lifetime DSM IV cocaine and opioid dependence status and the prevalence of BD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BD were found in 188/382 (42.9%) subjects and in 74/214 (34.6%) subjects. Three clinical factors were associated with BD in the whole sample: the number of cocaine dependence criteria (OR = 1.36 [1.14-1.64], p = 0.001), the number of opioid dependence criteria (OR = 0.69 [0.52-0.91], p = 0.010), and a personal history of using cocaine through rapid routes of administration (OR = 0.41 [0.19-0.88], p = 0.022). The same three factors were associated with "de novo" BD in the restricted sample: OR = 1.35 ([1.11-1.63], p = 0.002), OR = 0.83 ([0.70-0.99], p = 0.046), and OR 0.37 ([0.16-0.86], p = 0.022), respectively. There were significant gradients for BD according to the cocaine exposure categories in the whole (Mantel-Haenszel, p < 0.001) and in the restricted sample (Mantel-Haenszel, p = 0.002).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cocaine exposure was positively associated with behavioral disturbances in a dose-dependent manner in this clinical sample, whilst opioid exposure showed a negative association.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vorspan</LastName><ForeName>Florence</ForeName><Initials>F</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-5168-3727</Identifier><AffiliationInfo><Affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France. florence.vorspan@aphp.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculté de Médecine, Université de Paris, Paris, France. florence.vorspan@aphp.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France. florence.vorspan@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Witt</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Psychiatrie et d'Addictologie, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerdazi</LastName><ForeName>El-Hadi</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service d'Addictologie, DHU Pe-Psy, Pôle de psychiatrie et d'addictologie, Hôpitaux universitaires Henri MONDOR, APHP, F94000, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karsinti</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA 4430 CLIPSYD (Psychologie Clinique, Psychanalyse et Psychologie du Développement), UFR SPSE, Université Paris Nanterre, Nanterre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ksouda</LastName><ForeName>Kamilia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculté de Médecine de Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Icick</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, 200 rue du Faubourg Saint Denis, 75010, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculté de Médecine, Université de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marie</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Inserm UMR-S 1124, "Environmental Toxicity, Therapeutic Targets, Cellular Signaling and Biomarkers", Université de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS ERL 3649, "Addiction Pharmacology and Therapy", Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brousse</LastName><ForeName>Georges</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Inserm Umr 1107, Neuro-Dol, Université Clermont-Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloch</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Inserm UMR-S 1144 Therapeutic Optimization in Neurosychopharmacology, Université de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Pharmacie, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculté de Pharmacie de Paris, Université de Paris, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OST07013</GrantID><Agency>Direction de la Recherche et de l'Innovation (APHP)</Agency><Country></Country></Grant><Grant><GrantID>AOM10165</GrantID><Agency>Ministère Français de la Recherche, Programme Hospitalier de Recherche Cliniqu</Agency><Country></Country></Grant><Grant><GrantID>: COCAch (ERA-NET Neuron 2013, ANR-13</GrantID><Agency>European Commission</Agency><Country></Country></Grant><Grant><GrantID>ADIKHUMICE (ERA-NET Neuron 2017, ANR-17-NEU3-0002-05</GrantID><Agency>European Commission</Agency><Country></Country></Grant><Grant><GrantID>COCACE (ERA-NET Neuron 2014, ANR R14026KK)</GrantID><Agency>European Commission ()</Agency><Country></Country></Grant><Grant><GrantID>ANR-11-IDEX-0004-02</GrantID><Agency>Labex BioPSY (FR)</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychopharmacology (Berl)</MedlineTA><NlmUniqueID>7608025</NlmUniqueID><ISSNLinking>0033-3158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>I5Y540LHVR</RegistryNumber><NameOfSubstance UI="D003042">Cocaine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003042" MajorTopicYN="N">Cocaine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019970" MajorTopicYN="N">Cocaine-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="Y">Outpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADHD</Keyword><Keyword MajorTopicYN="N">Behavioral sensitization</Keyword><Keyword MajorTopicYN="N">Cocaine</Keyword><Keyword MajorTopicYN="N">Human</Keyword><Keyword MajorTopicYN="N">Opioids</Keyword><Keyword MajorTopicYN="N">Scales</Keyword><Keyword MajorTopicYN="N">Screening</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32748030</ArticleId><ArticleId IdType="doi">10.1007/s00213-020-05620-x</ArticleId><ArticleId IdType="pii">10.1007/s00213-020-05620-x</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>Tunisie</li></country><region><li>Auvergne (région administrative)</li><li>Auvergne-Rhône-Alpes</li><li>Île-de-France</li></region><settlement><li>Clermont-Ferrand</li><li>Créteil</li><li>Nanterre</li><li>Paris</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Vorspan, Florence" sort="Vorspan, Florence" uniqKey="Vorspan F" first="Florence" last="Vorspan">Florence Vorspan</name></region><name sortKey="Bellivier, Frank" sort="Bellivier, Frank" uniqKey="Bellivier F" first="Frank" last="Bellivier">Frank Bellivier</name><name sortKey="Bellivier, Frank" sort="Bellivier, Frank" uniqKey="Bellivier F" first="Frank" last="Bellivier">Frank Bellivier</name><name sortKey="Bellivier, Frank" sort="Bellivier, Frank" uniqKey="Bellivier F" first="Frank" last="Bellivier">Frank Bellivier</name><name sortKey="Bloch, Vanessa" sort="Bloch, Vanessa" uniqKey="Bloch V" first="Vanessa" last="Bloch">Vanessa Bloch</name><name sortKey="Bloch, Vanessa" sort="Bloch, Vanessa" uniqKey="Bloch V" first="Vanessa" last="Bloch">Vanessa Bloch</name><name sortKey="Bloch, Vanessa" sort="Bloch, Vanessa" uniqKey="Bloch V" first="Vanessa" last="Bloch">Vanessa Bloch</name><name sortKey="Brousse, Georges" sort="Brousse, Georges" uniqKey="Brousse G" first="Georges" last="Brousse">Georges Brousse</name><name sortKey="De Witt, Pauline" sort="De Witt, Pauline" uniqKey="De Witt P" first="Pauline" last="De Witt">Pauline De Witt</name><name sortKey="De Witt, Pauline" sort="De Witt, Pauline" uniqKey="De Witt P" first="Pauline" last="De Witt">Pauline De Witt</name><name sortKey="Icick, Romain" sort="Icick, Romain" uniqKey="Icick R" first="Romain" last="Icick">Romain Icick</name><name sortKey="Icick, Romain" sort="Icick, Romain" uniqKey="Icick R" first="Romain" last="Icick">Romain Icick</name><name sortKey="Karsinti, Emily" sort="Karsinti, Emily" uniqKey="Karsinti E" first="Emily" last="Karsinti">Emily Karsinti</name><name sortKey="Karsinti, Emily" sort="Karsinti, Emily" uniqKey="Karsinti E" first="Emily" last="Karsinti">Emily Karsinti</name><name sortKey="Karsinti, Emily" sort="Karsinti, Emily" uniqKey="Karsinti E" first="Emily" last="Karsinti">Emily Karsinti</name><name sortKey="Marie, Nicolas" sort="Marie, Nicolas" uniqKey="Marie N" first="Nicolas" last="Marie">Nicolas Marie</name><name sortKey="Marie, Nicolas" sort="Marie, Nicolas" uniqKey="Marie N" first="Nicolas" last="Marie">Nicolas Marie</name><name sortKey="Vorspan, Florence" sort="Vorspan, Florence" uniqKey="Vorspan F" first="Florence" last="Vorspan">Florence Vorspan</name><name sortKey="Vorspan, Florence" sort="Vorspan, Florence" uniqKey="Vorspan F" first="Florence" last="Vorspan">Florence Vorspan</name><name sortKey="Zerdazi, El Hadi" sort="Zerdazi, El Hadi" uniqKey="Zerdazi E" first="El-Hadi" last="Zerdazi">El-Hadi Zerdazi</name><name sortKey="Zerdazi, El Hadi" sort="Zerdazi, El Hadi" uniqKey="Zerdazi E" first="El-Hadi" last="Zerdazi">El-Hadi Zerdazi</name></country><country name="Tunisie"><noRegion><name sortKey="Ksouda, Kamilia" sort="Ksouda, Kamilia" uniqKey="Ksouda K" first="Kamilia" last="Ksouda">Kamilia Ksouda</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000272 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000272 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32748030
|texte= Chronic exposure to cocaine is associated with persistent behavioral disturbances. A cross-sectional dimensional study in outpatients with multiple substance use disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32748030" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |